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Abstract
This study investigated the behavioral effects in the forced swim test (FST) and the elevated plus-maze (EPM) of acute 
administration of WAY 161503 ([4aR]-8,9-dichloro-2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5[6H]-one), a selective 
5-HT2C receptor agonist with putative antidepressant-like properties. Fifteen minutes after intraperitoneal (i.p.) injections of 
either WAY 161503 (1, 3 and 10 mg/kg) or saline, naive male Wistar rats were exposed to the EPM for 5 min to assess classical 
and ethological anxiety-like measures. Immediately after EPM exposure, each animal was exposed to the FST, and the latency to 
the first episode of immobility was recorded (trial session). Twenty-four hours later, the rats were reexposed to a second EPM-
FST exposure sequence (test session for FST) under the effect of the same pharmacological treatment. The two lowest WAY 
161503 doses selectively reduced open-arm exploration and increased risk-assessment without affecting locomotor activity. 
This selective anxiogenic-like effect was observed in both the first and second EPM exposures. The highest WAY 161503 dose 
produced robust locomotor impairment. In the FST, the same WAY 161503 doses significantly increased the latency to the first 
immobility in the test session, a behavioral profile that suggests an antidepressant-like action. These results further support the 
involvement of 5-HT2C receptors in the mediation of anxiety and suggest an intricate relationship between anxiogenic- and 
antidepressant-like actions. Keywords: anxiety, depression, serotonin, 5-HT2C receptor agonist, WAY 161503, animal models.
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Introduction
The serotonin (5-hydroxytryptamine, 5-HT)2C 
receptor subtype appears to provide an interesting 
pharmacological target for screening new antidepressant 
agents. However, this possibility is based on contradictory 
findings showing the ability of both 5-HT2C agonists and 
antagonists to attenuate depression-related behaviors in 
animal models of depression. For example, acute and 
chronic 5-HT2C receptor activation by 5-HT2C agonists 
with different degrees of selectivity for the 5-HT2C receptor 
(e.g., WAY 161503, RO 60-0175, and RO 60-0332) are 
reported to decrease immobility in the rodent forced swim 
test (FST), an antidepressant-like effect comparable to 
selective serotonin reuptake inhibitors (Martin et al., 
1998; Cryan & Lucki, 2000; Rosenzweig-Lipson et 
al., 2007). 5-HT2C receptor blockade by nonselective, 
preferential, and selective 5-HT2C antagonists also 
appear to exhibit comparable antidepressant-like effects 
(Millan, 2005; Dekeyne et al., 2008). The reasons for 
these discrepancies remain unclear.
Interestingly, a different line of evidence suggests 
a critical role for the 5-HT2C receptor in the mediation 
of anxiety. For example, 5-HT2C receptor activation 
is relatively well documented to enhance anxiety-like 
parameters in humans (Charney, Woods, Goodman, 
& Heninger, 1987; Lowy & Meltzer 1988; Bourin, 
Baker, & Bradwejn, 1998) and animal models (Kennett, 
Whitton, Shah, & Curzon, 1989; Rodgers et al., 1992; 
Grewal, Shepherd, Bill, Fletcher, & Dourich, 1997; 
Mora, Ferreira Neto, & Graeff, 1997; Olivier et al., 1998; 
Setem, Pinheiro, Motta, Morato, & Cruz, 1999; Bagdy, 
Graf, Anheuer, Modos, & Kantor, 2001; Zangrossi et al., 
Gomes et al246
2001; Jones, Duxon, & King, 2002; Bull, Huston, & Fone, 
2003). 5-HT2C antagonists block these behavioral effects 
or induce anxiolytic-like actions themselves (for reviews, 
see Bourin & Dhonnchadha, 2005; Filip & Bader, 2009). 
Despite these two different lines of evidence 
indicating a major role for 5-HT2C receptors in 
depression and anxiety, little attention has been given 
to experimental procedures in which the same animal 
is successively exposed to models of anxiety and 
depression after the administration of 5-HT2C-acting 
compounds. The present study evaluated the behavioral 
effects of pharmacological 5-HT2C receptor activation 
by injecting the selective 5-HT2C agonist WAY 161503 
in rats successively exposed to the elevated plus maze 
(EPM) and FST, two of the most commonly used animal 
models of anxiety and depression, respectively.
Method
Subjects
A total of 32 naive male Wistar rats (3 months old, 
180-230 g bodyweight) from the animal colony of the 
University of Brasilia were housed in groups of four in 
polycarbonate cages (30 × 30 × 50 cm) with free access to 
food and water. The room temperature was controlled (25 
± 1ºC) under a 12 h/12 h light/dark cycle (lights on 07:00-
19:00). The maintenance, procedures, and minimal use 
of experimental animals followed the guidelines of the 
Brazilian Society of Neuroscience and Behavior under 
the recommendations of the Guide for the Care and Use 
of Laboratory Animals in Research (in accordance with 




Tocris, Ballwin, MO, USA) was dissolved in sterile 
saline (0.9% NaCl) and injected intraperitoneally (i.p.) 
in a volume of 1.0 ml/kg.
Apparatus
The EPM protocol followed the specifications 
described elsewhere (Cruz et al., 1994). It consisted of two 
open arms (50 × 10 cm) and two perpendicular closed arms 
(50 × 10 × 40 cm) connected and delimited by a central 
area (10 × 10 cm). The maze was elevated 50 cm from 
the floor, and a rim of Plexiglas (1 cm high) surrounded 
the perimeter of the open arms to minimize falling from 
the arms. Each rat was placed in the central area facing 
a closed arm and allowed to freely explore the maze for 
5 min. Before the next rat was introduced, the maze was 
cleaned with a solution of 20% ethanol and dried.
The rat FST apparatus was based on the specifications 
described by Porsolt, LePichnon, and Jalfre (1977) and 
Porsolt, Bertin, and Jalfre (1978) with some adaptations. 
Briefly, it consisted of a transparent cylinder (46 cm 
tall x 20 cm diameter) filled with water (26 ± 2°C) to 
a depth of 30 cm inside which the rats were placed and 
forced to swim without the opportunity for escape. They 
remained inside water until develop immobility, which 
was defined as the cessation of limb movements except 
those necessary to keep the animal afloat. 
Rats were tested in the FST with two exposures to 
the water tank spaced 24 h apart (trial session and test 
session, respectively). After swimming, each animal 
was gently dried with a towel and a hair blow dryer. The 
water in the tank was changed between rats.
Illumination (45 lux) was provided by a light bulb 
suspended above the apparatus. The EPM and FST 
sessions were videotaped for behavioral scoring at a later 
time by a blinded and highly experienced observer.
Procedure
Animals were handled daily for 5 min for 7 consecutive 
days. Following this habituation trial, they were randomly 
assigned to four groups and injected with either saline-
vehicle or WAY 161503 at doses of 1, 3, and 10 mg/kg. 
Fifteen minutes after the injections, each animal was 
exposed to the EPM for 5 min. The percentage of open-
arm entries (100 × open-arm entries/total arm entries) 
and the absolute number of closed-arm entries were 
calculated as indices of anxiety and locomotor activity, 
respectively. Behaviors related to risk assessment were 
additionally recorded on the basis of previous results from 
our laboratory showing that this measure is sensitive to 
serotonergic manipulations (Setem et al., 1999).
Immediately after EPM exposure, animals were 
transferred to the FST apparatus and forced to swim in 
the water. The latency to the first episode of immobility 
was recorded. Animals were then removed from the 
apparatus and returned to their home cage. On the 
next day, they were subjected to a second EPM-FST 
exposure sequence, 15 min after receiving the same 
pharmacological treatment. Reduced latency to the 
first episode of immobility in the test session compared 
with this same measure in the trial session, indicated 
depressive-like behavior in the FST (Contreras, Martinez-
Mota, & Saavedra, 1998; Contreras, Rodriguez-Landa, 
Gutierrez-Garcia, & Bernal-Morales, 2001; Mineur, 
Picciotto, & Sanacora, 2007).
Statistical analysis
The EPM and FST results were analyzed by two-
way analysis of variance (ANOVA) followed by 
Dunnett’s post hoc test when appropriate. Values of p < 
.05 were considered statistically significant.
Results
Figure 1 shows the behavioral effects of WAY 
161503 in the first and second EPM exposures. 
ANOVA indicated significant effects of treatment on the 
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percentage of open-arm entries (F [3, 48] = 12.74; p < 
.05), time spent engaging in risk assessment behaviors 
(F [3, 48] = 16.32; p < .05), and closed-arm entries (F 
[3, 48] = 9.42; p < .05), but no effect of EPM exposure.
Post hoc comparisons revealed that WAY 161503 
significantly reduced open-arm exploration at doses of 3 and 
10 mg/kg (ps < .05) and increased risk-assessment at doses 
of 1 and 3 mg/kg (ps < .05) compared with saline vehicle-
treated animals. At the dose of 10 mg/kg, this behavioral 
profile was accompanied by a significant reduction in the 
absolute number of closed-arm entries (p < .05). 
Figure 1. Behavioral effects of WAY-161503 in the first and 
second EPM exposures. Bars indicate the mean ± SEM (n = 8). 
*p < .05, #p < .05, significant difference compared with group 
treated with saline-vehicle.
Figure 2. Behavioral effects of WAY-161503 in the FST test 
session. Bars indicate the mean ± SEM (n = 8). *p < .05, significant 









































Figure 2 shows the effect of WAY 161503 on the 
latency to the first episode of immobility during the FST 
test session. ANOVA indicated a significant effect of 
treatment (F [3, 48] = 9.67; p < .05). Compared with 
animals injected with saline-vehicle, WAY 161503 
significantly increased the latency to the first episode of 
immobility at doses of 1 and 3 mg/kg and decreased this 
measure at 10 mg/kg (ps < .05).
Discussion
The role of 5-HT receptors in the mediation of 
emotional states has been widely investigated. Our 
results showed that 5-HT2C receptor activation by the 
selective 5-HT2C agonist WAY 161503 induced behavior 
consistent with anxiogenic- and antidepressant-like 
effects in the EPM and FST, respectively.
The anxiogenic-like action in the EPM was 
detected by decreased open-arm exploration at the 
dose of 3.0 mg/kg and increased risk-assessment 
behaviors from the closed arms at the doses of 1.0 
and 3.0 mg/kg. This enhanced anxiety seemed to be 
selective considering that these WAY 161503 doses did 
not affect the absolute number of closed arm entries at 
these doses, a reliable locomotor index in the rat EPM 
(Cruz et al., 1994). At the highest dose (10.0 mg/kg), 
however, the WAY 161503-induced changes in open 
arm exploration and risk-assessment were accompanied 
by a robust hypolocomotion as indicated by reduction 
in the absolute number of closed-arm entries. As a 
whole these results further corroborate previously 
reported studies showing selective, preferential and 
non-selective 5-HT2C agonists to exhibit anxiogenic-
like properties and locomotor impairments (Kennett 
et al. 1989; Rodgers et al. 1992; Grewal et al. 1997; 
Mora et al. 1997; Olivier et al. 1998; Setem et al. 1999; 
Bagdy et al. 2001; Zangrossi et al. 2001; Jones et al. 
2002; Bull et al. 2003; Alves et al., 2004). 
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Repeated EPM exposures are known to reduce or 
abolish the anxiolytic-like effects of benzodiazepines, 
a phenomenon known as “one-trail tolerance” or acute 
tolerance in this test (File, 1990; File & Zangrossi, 1993; 
File, 1993; File, Zangrossi, Viana, & Graeff, 1993; File, 
Gonzalez, & Gallant, 1999; Frussa-Filho & Ribeiro, 2002; 
Vargas, Da Cunha, & Andreatini, 2006; Albrechet-Souza, 
Borelli, & Brandão, 2008). Our present results with the 
5-HT2C agonist WAY 161503 showed that both the first 
and second EPM exposures were similarly able to detect 
anxiogenic-like effects. This result markedly contrasts 
with the one-trial tolerance phenomenon but corroborates 
previous studies in which one-trial tolerance in the EPM 
was evident after administration of anxiolytic but not 
anxiogenic drugs (File, 1993). A recent study reported by 
Wehrmeister, Izidio, Pereira, Izidio, & Ramos (2010) also 
found an absence of one-trial tolerance in rats exposed to 
a modified form of the EPM.
In the FST, WAY 161503 dose-dependently 
increased the latency to the first episode of immobility 
during the test session, a behavioral profile consistent 
with an antidepressant-like action. This was evident at 
the 1 and 3 mg/kg doses. At the highest dose (10 mg/
kg), the behavioral effects appeared to be attributable 
to general hypolocomotion, reflected by a reduction in 
closed-arm entries observed at this dose in the EPM. 
Similar antidepressant-like effects of acute and chronic 
administration with 5-HT2C agonists have been described 
in rodents exposed to animal models of depression, 
including the FST (Lucki, Ward, & Frazer, 1989; Martin 
et al., 1998; Cryan & Lucki, 2000; Rosenzweig-Lipson 
et al., 2007). In some of these studies, inhibitory effects 
on general locomotion were also described at higher 
doses (Lucki et al., 1989). 
In contrast to the above FST findings and our 
present results, subchronic pharmacological blockade 
of 5-HT2C receptors by preferential and selective 5-HT2C 
antagonists exhibited comparable antidepressant-like 
effects in the FST (Millan, 2005; Dekeyne et al., 2008). 
The reasons for these discrepancies remain unclear but 
might involve methodological issues, including acute, 
subchronic, and chronic forms of drug administration, 
the selectivity of the drugs for the 5-HT2C receptor 
subtype, and variations in the FST procedures. Further 
controlling and testing the behavioral effects of these 
variables are necessary.
In conclusion, our results showed that 5-HT2C 
receptor activation by the selective 5-HT2C agonist 
WAY 161503 enhanced anxiety-like behavior in the 
EPM but exerted a clear antidepressant-like effect in 
the FST, which might be associated with the therapeutic 
potential of WAY 161503 in the pharmacological 
treatment of depression. Such a pattern of results in 
these two widely used animal models might contribute 
to a better understanding of clinical findings, in which 
antidepressants have been shown to induce anxiety.
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